Role of Monotherapy with a P2Y12 Inhibitor for Secondary Prevention in Patients with Established Atherosclerosis

被引：0
|
作者：
Juan J. Rodriguez
Luis E. Baron
Oscar C. Munoz
Jonathan J. Diaz
机构：
[1] Texas Tech University Health Sciences Center,Facultad de Medicina
[2] Universidad Autonoma de Bucaramanga,Facultad de Medicina
[3] Universidad de Boyaca,undefined
来源：
Current Cardiology Reports | 2022年 / 24卷
关键词：
Monotherapy; Antiplatelet therapy; Atherosclerosic disease; Stroke; Myocardial infarction; Peripheral arterial disease; Secondary prevention;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：87 / 91
页数：4
相关论文
共 50 条
  • [21] Clinically Significant Differences Between P2Y12 Inhibitor Monotherapy and Aspirin Monotherapy Have Yet to Be Demonstrated
    Bates, Eric R.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (01) : e9 - e10
  • [22] P2Y12 INHIBITOR MONOTHERAPY OR DUAL ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH HYPERTENSION
    Pil-Sang, Song
    Jin-Ok, Jeong
    JOURNAL OF HYPERTENSION, 2023, 41 : E178 - E178
  • [23] Is clopidogrel as the P2Y12 inhibitor a wise choice for long- term monotherapy in patients undergoing stenting?
    Gurbel, Paul A.
    Tantry, Udaya S.
    EUROINTERVENTION, 2021, 17 (11) : E865 - E866
  • [24] P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients The MACT Pilot Study
    Lee, Seung-Yul
    Jeong, Young-Hoon
    Yun, Kyeong Ho
    Cho, Jae Young
    Gorog, Diana A.
    Angiolillo, Dominick J.
    Kim, Jin Won
    Jang, Yangsoo
    JACC-CARDIOVASCULAR INTERVENTIONS, 2023, 16 (15) : 1845 - 1855
  • [25] P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients: The MACT Pilot Study
    Lee, Seung-Yul
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 82 (17) : B18 - B18
  • [26] Purinergic receptors and atherosclerosis: emerging role for vessel wall P2Y12
    Rauch, Bernhard H.
    Filep, Janos G.
    CARDIOVASCULAR RESEARCH, 2014, 102 (03) : 339 - 341
  • [27] P2Y12 INHIBITORS VERSUS ASPIRIN FOR LONG-TERM SECONDARY PREVENTION OF ATHEROSCLEROSIS - A META-ANALYSIS
    Al-Abdouh, Ahmad
    Radaideh, Qais
    Abusnina, Waiel
    Mhanna, Mohammed
    Jabri, Ahmad
    Abu Rmilah, Anan
    Barbarawi, Mahmoud
    Obeidat, Khaldun
    Alzu'bi, Hossam
    Nasser, Mohamed Farhan
    Alnabelsi, Talal
    Paul, Timir K.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 1031 - 1031
  • [28] P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: Is It Safe to Abandon Aspirin?
    Feng, Wen-Han
    Hsieh, I-Chang
    Li, Yi-Heng
    ACTA CARDIOLOGICA SINICA, 2021, 37 (01) : 1 - 8
  • [29] Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors
    Girotra, Saket
    Stebbins, Amanda
    Wruck, Lisa
    Marquis-Gravel, Guillaume
    Gupta, Kamal
    Farrehi, Peter
    Benziger, Catherine P.
    Effron, Mark B.
    Whittle, Jeffrey
    Munoz, Daniel
    Kripalani, Sunil
    Anderson, David
    Jain, Sandeep K.
    Polonsky, Tamar S.
    Ahmad, Faraz S.
    Roe, Matthew T.
    Rothman, Russell L.
    Harrington, Robert A.
    Hernandez, Adrian F.
    Jones, W. Schuyler
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (20):
  • [30] Effect of Aspirin Dosing in Patients Treated With P2Y12 Inhibitors for Secondary Prevention of Cardiovascular Events
    Girotra, Saket
    Stebbins, Amanda
    Wruck, Lisa M.
    Riley, Danielle
    Kripalani, Sunil
    Munoz, Daniel
    Effron, Mark B.
    Gupta, Kamal
    Whittle, Jeffrey
    Benziger, Catherine
    Zhou, Li
    Farrehi, Peter M.
    Polonsky, Tamar S.
    Ahmad, Faraz S.
    Roe, Matthew T.
    Rothman, Russell
    Harrington, Robert A.
    Hernandez, Adrian F.
    Jones, William S.
    CIRCULATION, 2022, 146
12345